@Article{oncologie.2022.025226,
AUTHOR = {Xujie Zhou, Yuting Sang, Jiajian Chen, Miao Mo, Jianjing Hou, Benlong Yang, Jiong Wu},
TITLE = {Comparison of Time-Varying Pattern of Recurrence in Chinese Breast Cancer Patients with Different Molecular Subtypes: A Single-Center Retrospective Study},
JOURNAL = {Oncologie},
VOLUME = {24},
YEAR = {2022},
NUMBER = {3},
PAGES = {451--469},
URL = {http://www.techscience.com/oncologie/v24n3/49722},
ISSN = {1765-2839},
ABSTRACT = {<b>Background:</b> To compare the time-varying recurrence patterns of different molecular subtypes of breast cancer in
the contemporary era with those in the past era. <b>Patients and Methods:</b> This retrospective study included
14627 consecutive invasive breast cancer patients who underwent surgery from 2008 to 2016 at Fudan University
Shanghai Cancer Center. We defined the period from 2013 to 2016 as the contemporary era and that from 2008 to
2012 as the past era. Five subtypes were defined according to the immunohistochemistry results. Emphasis was
made on the changing patterns of recurrence for patients with different molecular subtypes changed between the
two treatment eras. Kaplan–Meier survival curves were generated, and the hazard function was used to estimate
the annual recurrence hazard. <b>Results:</b> By the end of follow-up (median, 68.1 months), 1429 patients (9.77%)
experienced recurrence and metastasis. The annual recurrence risks of the entire population and each molecular
type in 2013–2016 were reduced compared with those in 2008–2012. Luminal A and triple-negative patients in
2013–2016 showed a significantly lower recurrence hazard curve than those in 2008–2012. The recurrence hazard
curve of luminal B (HER2−) and HER2+ subtypes was lower in 2013–2016 than in 2008–2012. The recurrence
risk of the luminal B (HER2+) subtype was reduced substantially during 2013–2016, showing a delay of two years.
<b>Conclusions:</b> With early detection of disease recurrence and improved treatment strategies, the recurrence patterns of different molecular subtypes of breast cancer have changed. The time-varying recurrence patterns
observed during the contemporary era are significant for treatment decision-making and clinical trial planning.},
DOI = {10.32604/oncologie.2022.025226}
}